---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-014281"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T22:26:31.695186+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NeuroBo Q2 net loss narrows to $0.7M; DA-1241 Phase 2a dosing expected Sept 2023

## Summary
- Net loss of $0.7M ($0.02/share) in Q2 2023 vs $3.3M in Q2 2022; cash $28.7M sufficient into 2024.
- First patient dosing in Phase 2a trial of DA-1241 for NASH expected September 2023.
- Signed term sheet with MThera to out-license NB-01 for painful diabetic neuropathy worldwide except Korea.
- Preclinical data for DA-1726 shows superior weight loss vs semaglutide and tirzepatide; IND submission expected H2 2023.
- R&D expenses increased to $2.4M from $1.0M YoY, driven by DA-1241 preparation.

## SEC filing metadata
- accession: 0001558370-23-014281
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000155837023014281/0001558370-23-014281-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000155837023014281/nrbo-20230809x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-014281
- JSON: https://secwatch.observer/filing/0001558370-23-014281.json
- Plain text: https://secwatch.observer/filing/0001558370-23-014281.txt

## Key facts
- Earnings Releases
  MetaVia Inc. reported financial results for the second quarter ended June 30, 2023.
  - Period: the second quarter ended June 30, 2023
  - Result: reported results
  source text: NeuroBo Pharmaceuticals, Inc. (the “Company” ) issued a press release announcing its financial results for the second quarter ended June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1638287/000155837023014281/0001558370-23-014281-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.